Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption

— —

Hematti Peiman Sowmya Viswanathan (Associate Director, Cell Therapy Program, University Health Network, Toronto, ON, Canada)

Mesenchymal Stromal Cells

Translational Pathways to Clinical Adoption

Hematti Peiman, Sowmya Viswanathan (Associate Director, Cell Therapy Program, University Health Network, Toronto, ON, Canada)

$159.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
11 August 2016

Cellular physiology; Biotechnology

Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption provides the latest information on the necessary steps for successful production of stem cells for a clinical trial. Written by professionals with hands-on experience in bringing MSC therapies to the clinic, and building on the biology and mechanisms of action, this unique book covers the development and production of clinical-grade products that are suitable for use in humans. From design of a cell production facility, to obtaining regulatory approval and reimbursement issues, it is a useful guide for researchers and administrators across biomedical research.

Edited by: Hematti Peiman, Sowmya Viswanathan (Associate Director, Cell Therapy Program, University Health Network, Toronto, ON, Canada)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 234mm, Width: 191mm, Spine: 19mm
Weight: 770g
ISBN: 9780128028261
ISBN 10: 0128028262
Pages: 362
Publication Date: 11 August 2016
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

Dr. Peiman Hematti joined the Section of Hematology/Bone Marrow Transplantation at the University of Wisconsin-Madison in July 2004 as an Assistant Professor in the Department of Medicine. Dr. Hematti has completed a combined Internal Medicine/Pediatrics residency at the Cleveland Clinic Foundation and then Hematology fellowship at the National Heart, Lung and Blood Institute at the National Institutes of Health. His clinical interests are in inpatient care of hematopoietic stem cell transplant patients. He is the director of the clinical hematopoietic cell processing laboratory, and in that capacity oversees all the peripheral blood stem cell collections from the patients and processing of their products. Dr. Viswanathan has 10 years of experience leading multi-disciplinary teams of translational researchers, clinicians, nurses, manufacturing technicians, quality assurance manager, IT programmers and project managers who translate cell-based research into clinical trials. She specializes in commercial product development of biologics with specific expertise in stem cell translational research, preclinical pharmacology, GMP-compliant cell manufacturing of cell-based products, and working with regulatory agencies. She is currently Associate Director of the Cell Therapy Program at University Health Network in Toronto where she oversees the scientific, strategic, operational, regulatory, quality, pre-clinical strategy for the development of clinical-grade cells. In addition, Dr. Viswanathan works with the Center for Commercialization of Regenerative Medicine (CCRM), leading a vision for a Canada-wide national clinical program network, CellCan, that will concentrate on harmonizing practices, sharing strategies for clinical manufacturing of stem cells in Canada.